Gremubamab
Based on 1 Customer Validation
Gremubamab (MEDI3902) is a humanized IgG1 kappa anti-PcrV/Psl monoclonal antibody. Gremubamab binds to the PA PcrV protein and Psl exopolysaccharide. Gremubamab has the potential for the research of pseudomonas aeruginosa infections.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 98.40%
- No. CAS: 1800381-36-5
- Peso molecular:200.46 kDa
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Actividad biológica
-
Chemical Information
- Pureza y Documentación
- Referencias
-
Help & FAQs
Actividad biológica
[VH-CH1-scFv-VH-VK-h-CH2-CH3_L-kappa]2
Pseudomonas aeruginosa
PcrV & PslG
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Rabbits (acute pneumonia model)[2]
-
Dosage:1, 5, 15 mg/kg
-
Administration:I.v.; at 1 h postinfection
-
Result:Improved survival outcomes in a dose-dependent manner in a rabbit acute pneumonia model.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
[VH-CH1-scFv-VH-VK-h-CH2-CH3_L-kappa]2
ELISA, FACS, Functional assay
-
Immobilized Pseudomonas aeruginosa can bind Gremubamab. The EC50 for this effect is 136.6 ng/mL.
Chemical Information
-
No. CAS 1800381-36-5
-
Appearance Liquid
-
Peso molecular 200.46 kDa
-
Color Colorless to light yellow
-
SMILES
[Gremubamab]
-
Synonyms
MEDI3902
-
Envío
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
-
Ficha de datos (257 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Referencias
[1]. Chastre J, et al. Safety, efficacy, and pharmacokinetics of gremubamab (MEDI3902), an anti-Pseudomonas aeruginosa bispecific human monoclonal antibody, in P. aeruginosa-colonised, mechanically ventilated intensive care unit patients: a randomised controlled trial. Crit Care. 2022 Nov 15;26(1):355. [Content Brief]
[2]. Le HN, et al. Treatment Efficacy of MEDI3902 in Pseudomonas aeruginosa Bloodstream Infection and Acute Pneumonia Rabbit Models. Antimicrob Agents Chemother. 2019 Jul 25;63(8):e00710-19. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz